Literature DB >> 21028935

Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.

Anthony E Kline1, Rose L McAloon, Kate A Henderson, Utsav K Bansal, Bhaskar M Ganti, Rashid H Ahmed, Robert B Gibbs, Christopher N Sozda.   

Abstract

When provided individually, both the serotonin (5-HT(1A))-receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and environmental enrichment (EE) enhance behavioral outcome and reduce histopathology after experimental traumatic brain injury (TBI). The aim of this study was to determine whether combining these therapies would yield greater benefit than either used alone. Anesthetized adult male rats received a cortical impact or sham injury and then were randomly assigned to enriched or standard (STD) housing, where either 8-OH-DPAT (0.1 mg/kg) or vehicle (1.0 mL/kg) was administered intraperitoneally once daily for 3 weeks. Motor and cognitive assessments were conducted on post-injury days 1-5 and 14-19, respectively. CA1/CA3 neurons and choline acetyltransferase-positive (ChAT(+)) medial septal cells were quantified at 3 weeks. 8-OH-DPAT and EE attenuated CA3 and ChAT(+) cell loss. Both therapies also enhanced motor recovery, acquisition of spatial learning, and memory retention, as verified by reduced times to traverse the beam and to locate an escape platform in the water maze, and a greater percentage of time spent searching in the target quadrant during a probe trial in the TBI + STD + 8-OH-DPAT, TBI + EE + 8-OH-DPAT, and TBI + EE + vehicle groups versus the TBI + STD + vehicle group (p ≤ 0.0016). No statistical distinctions were revealed between the TBI + EE + 8-OH-DPAT and TBI + EE + vehicle groups in functional outcome or CA1/CA3 cell survival, but there were significantly more ChAT(+) cells in the former (p = 0.003). These data suggest that a combined therapeutic regimen of 8-OH-DPAT and EE reduces TBI-induced ChAT(+) cell loss, but does not enhance hippocampal cell survival or neurobehavioral performance beyond that of either treatment alone. The findings underscore the complexity of combinational therapies and of elucidating potential targets for TBI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21028935      PMCID: PMC2978058          DOI: 10.1089/neu.2010.1535

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  87 in total

Review 1.  Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease.

Authors:  Alessia Lanari; Francesco Amenta; Giorgio Silvestrelli; Daniele Tomassoni; Lucilla Parnetti
Journal:  Mech Ageing Dev       Date:  2005-11-16       Impact factor: 5.432

2.  The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window.

Authors:  Jeffrey P Cheng; Haris A Aslam; Ann N Hoffman; Ross D Zafonte; Anthony E Kline
Journal:  Neurosci Lett       Date:  2007-02-07       Impact factor: 3.046

3.  Environmental enrichment-mediated functional improvement after experimental traumatic brain injury is contingent on task-specific neurobehavioral experience.

Authors:  Ann N Hoffman; Rebecca R Malena; Brian P Westergom; Pallavi Luthra; Jeffrey P Cheng; Haris A Aslam; Ross D Zafonte; Anthony E Kline
Journal:  Neurosci Lett       Date:  2007-12-04       Impact factor: 3.046

Review 4.  The role of acetylcholine in learning and memory.

Authors:  Michael E Hasselmo
Journal:  Curr Opin Neurobiol       Date:  2006-09-29       Impact factor: 6.627

5.  Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep.

Authors:  Barry W Row; Leila Kheirandish; Yu Cheng; Peter P Rowell; David Gozal
Journal:  Behav Brain Res       Date:  2007-01-10       Impact factor: 3.332

6.  Magnesium and riboflavin combination therapy following cortical contusion injury in the rat.

Authors:  Adrianne B Barbre; Michael R Hoane
Journal:  Brain Res Bull       Date:  2006-04-03       Impact factor: 4.077

7.  Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.

Authors:  Anthony E Kline; Amy K Wagner; Brian P Westergom; Rebecca R Malena; Ross D Zafonte; Adam S Olsen; Christopher N Sozda; Pallavi Luthra; Monisha Panda; Jeffery P Cheng; Haris A Aslam
Journal:  Behav Brain Res       Date:  2006-12-12       Impact factor: 3.332

8.  Voluntary exercise or amphetamine treatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats.

Authors:  G S Griesbach; D A Hovda; F Gomez-Pinilla; R L Sutton
Journal:  Neuroscience       Date:  2008-04-09       Impact factor: 3.590

9.  Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003.

Authors:  Anbesaw W Selassie; Eduard Zaloshnja; Jean A Langlois; Ted Miller; Paul Jones; Claudia Steiner
Journal:  J Head Trauma Rehabil       Date:  2008 Mar-Apr       Impact factor: 2.710

10.  A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning.

Authors:  Jeffrey P Cheng; Ann N Hoffman; Ross D Zafonte; Anthony E Kline
Journal:  Behav Brain Res       Date:  2008-07-01       Impact factor: 3.332

View more
  42 in total

1.  Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT1A receptor agonist buspirone after experimental traumatic brain injury.

Authors:  Anthony E Kline; Adam S Olsen; Christopher N Sozda; Ann N Hoffman; Jeffrey P Cheng
Journal:  J Neurotrauma       Date:  2012-05-21       Impact factor: 5.269

2.  Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.

Authors:  Adam S Olsen; Christopher N Sozda; Jeffrey P Cheng; Ann N Hoffman; Anthony E Kline
Journal:  J Neurotrauma       Date:  2012-04-23       Impact factor: 5.269

Review 3.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

4.  A relatively brief exposure to environmental enrichment after experimental traumatic brain injury confers long-term cognitive benefits.

Authors:  Jeffrey P Cheng; Kaitlyn E Shaw; Christina M Monaco; Ann N Hoffman; Christopher N Sozda; Adam S Olsen; Anthony E Kline
Journal:  J Neurotrauma       Date:  2012-08-27       Impact factor: 5.269

Review 5.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

Review 6.  Found in translation: Understanding the biology and behavior of experimental traumatic brain injury.

Authors:  Corina O Bondi; Bridgette D Semple; Linda J Noble-Haeusslein; Nicole D Osier; Shaun W Carlson; C Edward Dixon; Christopher C Giza; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2014-12-10       Impact factor: 8.989

7.  Abbreviated environmental enrichment confers neurobehavioral, cognitive, and histological benefits in brain-injured female rats.

Authors:  Hannah L Radabaugh; Lauren J Carlson; Darik A O'Neil; Megan J LaPorte; Christina M Monaco; Jeffrey P Cheng; Patricia B de la Tremblaye; Naima Lajud; Corina O Bondi; Anthony E Kline
Journal:  Exp Neurol       Date:  2016-09-28       Impact factor: 5.330

8.  Intermittent treatment with haloperidol or quetiapine does not disrupt motor and cognitive recovery after experimental brain trauma.

Authors:  Jillian J Weeks; Lauren J Carlson; Hannah L Radabaugh; Patricia B de la Tremblaye; Corina O Bondi; Anthony E Kline
Journal:  Behav Brain Res       Date:  2016-09-21       Impact factor: 3.332

9.  Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats.

Authors:  Kaitlyn E Shaw; Corina O Bondi; Samuel H Light; Lire A Massimino; Rose L McAloon; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2013-03-26       Impact factor: 5.269

Review 10.  5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Authors:  Jeffrey P Cheng; Jacob B Leary; Aerin Sembhi; Clarice M Edwards; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2015-11-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.